Compare Immunogenicity & Safety of 3 Lots of GSK208141 Vaccine in Healthy HSV-1 & -2 Seronegative (HSV 1-/2-) Females of 10-17 y & Vaccine Immunogenicity in Healthy HSV 1-/2- Females of 10-17 y With Healthy HSV 1 /2- Adult Females.
Phase of Trial: Phase III
Latest Information Update: 28 Sep 2016
At a glance
- Drugs GSK 208141 (Primary)
- Indications Herpes simplex virus type 1 infections; Herpes simplex virus type 2 infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 06 Nov 2008 Actual patient number changed 554 to 671 from as reported by ClinicalTrials.gov.
- 22 Aug 2008 New trial record.